Search company, investor...

Founded Year



Grant | Alive

Total Raised


Last Raised

$1.8M | 1 yr ago

About Eascra Biotech

Eascra Biotech is a company focused on the development of innovative therapeutic nanotechnologies in the biotechnology sector. The company's main offerings include highly effective, super biocompatible solutions based on DNA nanotechnology, which are designed to enhance therapeutic delivery and regenerative medicine for a variety of chronic conditions such as articular cartilage, central nervous system disorders, and solid tumors. These solutions are a cost-effective alternative to existing options and can be customized to enhance the therapeutic efficacy of drug treatments. It was founded in 2021 and is based in Boston, Massachusetts.

Headquarters Location

139A Charles Street Suite 315

Boston, Massachusetts, 02114,

United States




Latest Eascra Biotech News

Eascra Biotech Research Blasts Off with Ax-2 Launch

May 20, 2023

Eascra Biotech Exploring Space Manufacturing Options on the International Space Station BOSTON, May 19, 2023... The post Eascra Biotech Research Blasts Off with Ax-2 Launch first appeared on IT Business Net.

Eascra Biotech Frequently Asked Questions (FAQ)

  • When was Eascra Biotech founded?

    Eascra Biotech was founded in 2021.

  • Where is Eascra Biotech's headquarters?

    Eascra Biotech's headquarters is located at 139A Charles Street, Boston.

  • What is Eascra Biotech's latest funding round?

    Eascra Biotech's latest funding round is Grant.

  • How much did Eascra Biotech raise?

    Eascra Biotech raised a total of $1.8M.

  • Who are the investors of Eascra Biotech?

    Investors of Eascra Biotech include NASA.



CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.